Navigation Links
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Date:10/19/2009

red with an increase of 1.37 (+/- 4.56) score in the group receiving placebo plus methotrexate (P<0.015). The reduction in progression of vdH-S scores seen with the 50 mg and 100 mg doses was comparable.

In a second study, the GOlimumab FOR subjects With Active RA Despite Methotrexate (GO-FORWARD) clinical trial, vdH-S changes from baseline were minimal in all groups studied (including the placebo arm) which prevented any significant effect of SIMPONI to be detected. A lack of progression in the placebo group may have been due to the short placebo-controlled period of the trial and relatively less active patient population than in previously reported RA trials.

Psoriatic Arthritis

In the Golimumab - A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL) trial, patients with active PsA receiving SIMPONI 50 mg showed significantly less progression of structural damage at week 24 compared with patients receiving placebo plus methotrexate, and the benefit was maintained through 52 weeks. Structural damage was measured using the vdH-S score. The mean change (+/- standard deviation) from baseline in patients receiving SIMPONI was a decrease of 0.16 (+/- 1.31) score at week 24 compared with an increase of 0.27 (+/- 1.26) score in the placebo group (P=0.011). At week 24 all placebo patients began receiving SIMPONI 50 mg. At week 52, the mean change from baseline in total vdH-S score was -0.22 (+/- 1.64) in patients initially randomized to SIMPONI 50 mg at baseline while the mean score in the group who crossed over from placebo to SIMPONI at week 24 was 0.22 (+/- 1.38).

"Results from the GO-REVEAL study show that treatment with golimumab inhibited joint destruction in patients with active psoriatic arthritis," said Dr. Arthur Kavanaug
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
2. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd
4. Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN, LLC
5. ClinfoSource and California State University, East Bay Jointly Launch On-Line Certificate Program in Clinical Research
6. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
7. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
8. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
9. NIH funds support UAB joint replacement research
10. Health Robotics Expands and Diversifies Global Channel Strategies With Joint-Ventures & Direct Operations
11. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... , BATON ROUGE, La., Sept. 10 ... that it has begun enrollment and dosing of patients ... with advanced solid tumors. EP-100, the lead candidate from ... targeted membrane-disrupting peptide (tMDP) designed to seek and destroy ...
... , , , ... HEV ) Advanced lithium-ion battery maker EnerDel, Inc. today ... leader with 30 years, global manufacturing and management experience and a ... of three new executive appointments designed to position EnerDel for continued ...
... news release, "Clinical Therapeutics Announces the Addition of,Michael G. ... & Maternal Therapeutics Section" issued on 9 Sep 2009 ... advised by a representative,of the company that the Dateline ... and the contact number has been changed from,+44(0)908-547-2094 to ...
Cached Biology Technology:Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 2Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 3Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6/C O R R E C T I O N -- Clinical Therapeutics/ 2/C O R R E C T I O N -- Clinical Therapeutics/ 3/C O R R E C T I O N -- Clinical Therapeutics/ 4/C O R R E C T I O N -- Clinical Therapeutics/ 5
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... The University of Delaware, in collaboration with Stroud ... $4.3 million grant from the National Science Foundation to ... Zone Observatory" for researching questions relating to climate change. ... of the planet from the treetops to the groundwater ...
... 2009, Rockville, Md. Counterfeit and adulterated food and ... them emerged as key themes of the Annual Scientific ... Held in Toronto, Canada, more than 300 people from ... Experts from all countries need to grapple with the ...
... Richard Feinman, PhD, professor of biochemistry and of family medicine ... speak at the annual conference of the European Association for ... is holding its annual conference September 28 October 2 ... four speakers covering the topic, Controversies in Dietary Strategies in ...
Cached Biology News:Critical Zone Observatory seeks to answer climate change questions 2Critical Zone Observatory seeks to answer climate change questions 3Critical Zone Observatory seeks to answer climate change questions 4Global public health the focus of scientific conference 2
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
... Fully automated microarray slide processing ... The trend to miniaturization, automation ... technology a powerful tool with many ... settings. These applications range from gene ...
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... Blot Kits overcome this limitation and offer ... wide range in low-density protein array (96- ... are ideal for performing reverse-phase protein arrays ... the presence of low abundant antigens. Protein ...
Biology Products: